NCT01025063已完成不适用
Use of Spectral OCT in Combination Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 主要终点
- This pilot study observed anatomical measures which are currently not defined since the new technology is unclear in regards to what changes are seen at the level of the RPE and photoreceptors.
研究概览
简要总结
This study will investigate the safety and efficacy of treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) with a combination of ranibizumab (Lucentis) and verteporfin PDT (Visudyne), as compared with ranibizumab monotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to give informed consent
- •Patients with visual acuity of 20/40-20/320 in the study eye
- •Subfoveal choroidal neovascularization (CNV) must be at least 50% of the total lesion size.
- •Total area of lesion components other that CNV must be less than 50% of the total lesion size.
- •The lesion must be < 5400microns in greatest linear dimension (GLD).
- •Lesion size < 10 DA
- •Occult with no classic CNV lesions must have presumed recent disease progression:
- •Blood associated with the lesion at baseline
- •Loss of visual acuity in the previous 3 months: a: > 5 letter loss (ETDRS equivalent) or b: 2 or more lines using a snellen or equivalent chart
- •> 10% increase in GLD as assessed by fluorescein angiography in the previous 3 months
排除标准
- •Presence of angioid streaks, presumed ocular histoplasmosis syndrome, pathologic myopia (-8 or more with evidence of posterior segment abnormalities consistent with pathologic myopia), or CNV secondary to causes other than AMD
- •Geographic atrophy in the study eye
- •Tear (rip) of the retinal pigment epithelium
- •Presence of fibrosis, hemorrhage, pigment epithelial detachments, or other hypofluorescent lesions obscuring greater than 50% of the CNV lesion
- •Intraocular surgery within 6 weeks of enrollment
- •Active or history of ocular inflammation or infection in the study eye within the last 30 days
- •Subretinal hemorrhage > 50% of the total lesion
- •History of submacular surgery, or transpupillary thermotherapy in the study eye
- •Patients with intraocular pressure greater than 30 mm/Hg on 2 pressure-lowering medications
- •Patients with severe disciform scarring
- •History of intraocular surgery in the study eye including pars plana vitrectomy, except for uncomplicated cataract surgery within 60 days prior to screening
- •History of YAG laser posterior capsulotomy in the study eye within 30 days prior to screening
- •Inability to make study visits
- •Advanced glaucoma, uncontrolled glaucoma in the study eye (defined as intraocular pressure, IOP ≥ 25 mmHg) despite treatment with two or more topical pharmacological anti-glaucomatous medication)
- •Allergies to porphyrins or a known hypersensitivity to any component of Visudyne®
- •Patients with porphyria
- •Pregnancy or lactation
结局指标
主要结局
This pilot study observed anatomical measures which are currently not defined since the new technology is unclear in regards to what changes are seen at the level of the RPE and photoreceptors.
时间窗: 3 months
次要结局
未报告次要终点
研究者
Rhonda Weeks
Gaurav K. Shah, MD
Barnes Retina Institute
相似试验
已完成
2 期
Combination Therapy for Age-Related Macular Degeneration.Age Related Macular DegenerationNCT00376701Lawson Health Research Institute103
Unknown
2 期
Conbercept in Choroidal Neovascularization Secondary to UveitisChoroidal NeovascularizationUveitisNCT02934841Chongqing Medical University40
进行中（未招募）
不适用
Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary InterventionCoronary VesselsNCT03394079Seung-Jung Park2,008
已完成
2 期
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized RegimenChoroidal NeovascularisationNCT01037348Novartis65
已完成
4 期
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular DegenerationRetinal Pigment Epithelial DetachmentChoroidal NeovascularizationNCT01628354University of Melbourne49